ArticleCancers2021

Assessment of Resistance Mechanisms and Clinical Implications in Patients with KRAS Mutated-Metastatic Breast Cancer and Resistance to CDK4/6 Inhibitors.

Lucrezia Raimondi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.